Apellis Pharmaceuticals

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

Achillion

This pharmaceutical company develops oral small molecule complement inhibitors to treat patients with rare diseases such as paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

True North Therapeutics

This biotechnology company develops monoclonal antibodies targeting the complement system to treat patients with rare blood, kidney and skin diseases.

Annexon Biosciences

This biopharmaceutical company develops complement-based therapies for patients with autoimmune, neurodegenerative and ophthalmic diseases of the body, brain and eye.

Calliditas therapeutics

This biopharmaceutical company develops and commercialises medicines for patients with rare renal and hepatic diseases.

AUPH

The company develops and provides pharmaceutical therapies for adult patients living with autoimmune diseases such as active lupus nephritis.

Optherion

The company develops diagnostic tools and therapeutics for age-related macular degeneration and rare renal diseases for patients and healthcare providers.

Oculis

This biopharmaceutical company develops topical therapies and delivery systems to treat neuro-ophthalmic and ophthalmic diseases for patients with unmet medical needs.